EI
LXEO icon

Ethic Inc’s Lexeo Therapeutics LXEO Stock Holding History

Ethic Inc’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63.9K Sell
11,132
-317
-3% -$2.25K ﹤0.01% 1212
2025
Q4 		$114K Buy
11,449
+130
+1% +$1.19K ﹤0.01% 1170
2025
Q3 		$75.2K Buy
11,319
+593
+6% +$2.87K ﹤0.01% 1163
2025
Q2 		$44.2K Buy
+10,726
New +$35.3K ﹤0.01% 1193

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ethic Inc's LXEO Position: Q1 2026 in Review

Ethic Inc reduced its Lexeo Therapeutics (LXEO) stake by 2.8% in Q1 2026, selling an estimated $2.25K and leaving 11,132 shares worth $63.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1212.

Ethic Inc first reported a position in LXEO in Q2 2025 and has held it in 4 quarters since. The position peaked at $114K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Ethic Inc held 11,132 shares of Lexeo Therapeutics worth $63.9K as of Q1 2026.
  • Ethic Inc sold 317 Lexeo Therapeutics shares in Q1 2026, an estimated $2.25K.
  • Lexeo Therapeutics made up ﹤0.01% of Ethic Inc's portfolio in Q1 2026, its #1212 holding.
  • Ethic Inc first reported a position in Lexeo Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Ethic Inc's Lexeo Therapeutics position peaked at $114K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Ethic Inc's 13F filing for Q1 2026, filed 27 Apr 2026.